LGVN Longeveron Inc - Ordinary Shares - Class A
11,958
$1.28
$0.01
(0.78%)
| Watchers | 11,958 |
| 52-Wk Low | $1.24 |
| 52-Wk High | $40.00 |
| Market Cap | $4.16M |
| Volume | 232,595.00 |
| 52-Wk High | $40.00 |
| 52-Wk Low | $1.24 |
Why Longeveron (LGVN) Stock Exploded Higher TodayBenzinga • about 1 month ago
Longeveron shares are trading higher Monday afternoon. The company announced it submitted paperwork for a share offering.
read more...
Share to Feed
Gagnants
L'action Etao International Co (NASDAQ:ETAO) a grimp lundi de 104,93% 5,11 dollars lors de la session ordinaire.
L'action Longeveron (NASDAQ:LGVN) a augment de 57,73% 3,47...
Titoli in rialzo
Il titolo Etao International Co (NASDAQ:ETAO) ha avuto un aumento dell'111,47% a 5,27 dollari durante la sessione regolare di luned .
Le azioni di Longeveron (NASDAQ:LGVN) hanno...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Longeveron Inc. (NASDAQ:LGVN Free Report) shares are going to reverse split on the morning of Wednesday, March 27th. The 1-10 reverse split was announced on Wednesday, March 27th. The number...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Even though Longeveron Inc. ( NASDAQ:LGVN ) has fallen by 12% over the past week , insiders who sold US$82k worth of...
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B in HLHS Continues Enrollment; Completion of...
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical...